Malaysia is also considering dropping negotiations to procure a single-dose vaccine from U.S. pharmaceutical firm Johnson & Johnson, in favour of a deal with Chinese company CanSino Biologics, which also requires only one dose, Khairy said.

"This is a better option for us compared to Johnson & Johnson, where supplies are expected to arrive only in the fourth quarter of the year," he said.

Today CansinoBio stock rose 18% due to positive Phase 3 test result. Gov aim to procure 3.5mil for Cansino vaccine. Solution order agreement 10-15mil with Cansino include local order and for regional export. With surging cases numbers, global delay from Pfizer, and export ban by EU (which affect MY & SG) there will be potential increase demands from local gov and regional countries for China vacs. The advantage for Cansino compare to others is single dose vacs which benefits in terms of cost, logistics & vacs process. Moreover gov to reevaluate Sinovac vaccine due to recent efficacy report. Cansino & Solution agreement include local F&F and hub for regional export

Patience is key everyone, good things will come

https://www.globaltimes.cn/page/202102/1214559.shtml

Solution Group Bhd has obtained shareholders approval to diversify into pharmaceutical-related business at its EGM on Friday.

Its wholly-owned subsidiary Solution Biologics Sdn Bhd (SolBio) on Sept 23 entered into an agreement with CanSino Biologics Inc for both parties to collaborate on the manufacturing and commercialisation of the latter’s Covid-19 vaccine.

It has also obtained approval from the Health Ministry’s National Pharmaceutical Regulatory Agency for a design plan and layout of its vaccine fill and finish facility.

https://www.thestar.com.my/business/business-news/2021/01/16/pharmaceutical-companies-in-the-limelight

1) The company's vaccine fill and finish project is currently developing smoothly, everything is in progress, and equipment for bottled cans is being installed at this stage


2) The company's vaccine sales strategy will not only rely on Malaysia, but will also focus on opening up the Southeast Asian market. It has already contacted some countries, but so far, no other Southeast Asian governments have placed orders.


3) Solutn is expected to produce nearly 30-40m doses of vaccine this year (canSino provides bulk vaccine)


4) Assuming that after the Chinese government officially signs the order, other governments may follow suit


5) The company is also applying for halal certification with the State Administration of Religious Affairs. No animal materials were involved in the vaccine manufacturing process.

6) For Pharmaniaga-Sinovac, a newly added vaccine warfare, the company said that there is definitely competition, but Solutn's Cansino vaccine has advantages. In addition to advanced technology, it also has the advantage of "one dose" (other vaccines require two doses) , Combined, plus storage and transportation, the cost is expected to be lower than other brands.

7) The company will obtain the interim data of CanSino's third phase trial at the end of January or early February, and then submit it to the Drug Administration for registration.

1 Gov buy Cansino vaccine thru Solution
2 Better Margin than others
3 Local distribution partners and plan announce very soon for private sector market
4 Cansino Russia Trail result announce very soon & submit the data to NPRA around early Feb
5 Solution has been working with other ASEAN countries' local companies to get in touch with their Gov

should be strong enough to hold the share, right? haha